AliveCor has acquired an independent diagnostic testing facility (IDTF), CardioLabs, to expand its cardiological services to patients who are using monitoring devices prescribed by healthcare specialists.
An electrocardiogram (ECG) technology and services provider, AliveCor now handles CardioLabs’ healthcare provider clients in the US and intends to also extend the service to new users soon.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Current customers of CardioLabs will retain access to the suite of cardiac monitoring services that are already available to them. These services include the mobile cardiac telemetry, cardiac event monitoring and extended holter and holter monitoring.
In the long run, CardioLabs customers will gain access to AliveCor’s KardiaMobile 6L, which is said to be the first wireless, patchless, six-lead cardiac monitor.
In March last year, KardiaMobile 6L technology received the US Food and Drug Administration (FDA) approval to measure corrected QT interval (QTc) and detect potentially dangerous QT prolongation in Covid-19 patients.
AliveCor CEO Priya Abani said: “The acquisition of CardioLabs sets AliveCor on a course to becoming the premier provider of end-to-end cardiac diagnostic support.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“We are creating new opportunities for healthcare providers and patients through enhanced, reimbursed cardiac monitoring services and access to real-time data that helps inform clinical decision-making.”
Last month, the US International Trade Commission (ITC) announced a probe into Apple’s alleged infringement of three AliveCor patents.
AliveCor filed the case with the ITC in April, claiming patent violation and seeking to stop Apple Watches with the infringing technology integrated being imported into the US.
An inquiry was launched to investigate whether Apple illegally used the patented electrocardiogram monitor technology of AliveCor.
AliveCor also filed a federal antitrust lawsuit against Apple over its omission of other heartrate analysis providers from the Apple Watch.
The complaint alleged that the monopolistic conduct of Apple harmed AliveCor, as well as its patients and users.
In 2015, AliveCor launched KardiaBand, the first FDA-cleared accessory for Apple Watch, along with the SmartRhythm app.
The app works by consuming data from the Apple Watch’s heart rate algorithm to identify if a user has an irregular heartbeat and suggest an ECG test.
According to the lawsuit, Apple copied AliveCor’s technology and changed the ‘watchOS’ operating system to damage the company as well as other rival apps.
